Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer
- PMID: 21963846
- DOI: 10.1038/onc.2011.429
Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer
Abstract
Tissue transglutaminase (TG2), an enzyme involved in cell proliferation, differentiation and apoptosis is overexpressed in ovarian carcinomas, where it modulates epithelial-to-mesenchymal transition (EMT) and promotes metastasis. Its regulation in ovarian cancer (OC) remains unexplored. Here, we show that transforming growth factor (TGF)-β, a cytokine involved in tumor dissemination is abundantly secreted in the OC microenvironment and induces TG2 expression and enzymatic activity. This is mediated at transcriptional level by SMADs and by TGF-β-activated kinase 1-mediated activation of the nuclear factor-κB complex. TGF-β-stimulated OC cells aggregate as spheroids, which enable peritoneal dissemination. We show that TGF-β-induced TG2 regulates EMT, formation of spheroids and OC metastasis. TG2 knock-down in OC cells decreases the number of cells harboring a cancer stem cell phenotype (CD44+/CD117+). Furthermore, CD44+/CD117+ cells isolated from human ovarian tumors express high levels of TG2. In summary, TGF-β-induced TG2 enhances ovarian tumor metastasis by inducing EMT and a cancer stem cell phenotype.
Similar articles
-
Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.Neoplasia. 2013 Jun;15(6):609-19. doi: 10.1593/neo.121878. Neoplasia. 2013. PMID: 23730209 Free PMC article.
-
Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase.Cancer Res. 2009 Dec 15;69(24):9192-201. doi: 10.1158/0008-5472.CAN-09-1257. Cancer Res. 2009. PMID: 19951993
-
Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.Oncotarget. 2017 Mar 21;8(12):20025-20041. doi: 10.18632/oncotarget.15370. Oncotarget. 2017. PMID: 28223538 Free PMC article.
-
Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer.Breast Cancer Res. 2013 Feb 25;15(1):202. doi: 10.1186/bcr3371. Breast Cancer Res. 2013. PMID: 23673317 Free PMC article. Review.
-
Transglutaminase is a tumor cell and cancer stem cell survival factor.Mol Carcinog. 2015 Oct;54(10):947-58. doi: 10.1002/mc.22375. Epub 2015 Aug 10. Mol Carcinog. 2015. PMID: 26258961 Free PMC article. Review.
Cited by
-
Defining the Role of Metastasis-Initiating Cells in Promoting Carcinogenesis in Ovarian Cancer.Biology (Basel). 2023 Dec 5;12(12):1492. doi: 10.3390/biology12121492. Biology (Basel). 2023. PMID: 38132318 Free PMC article. Review.
-
Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches.Int J Mol Sci. 2023 Jun 26;24(13):10683. doi: 10.3390/ijms241310683. Int J Mol Sci. 2023. PMID: 37445860 Free PMC article. Review.
-
PARP3 comes to light as a prime target in cancer therapy.Cell Cycle. 2019 Jun;18(12):1295-1301. doi: 10.1080/15384101.2019.1617454. Epub 2019 May 29. Cell Cycle. 2019. PMID: 31095444 Free PMC article. Review.
-
Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine.Genes Dis. 2020 Dec 1;9(3):668-681. doi: 10.1016/j.gendis.2020.11.017. eCollection 2022 May. Genes Dis. 2020. PMID: 35782973 Free PMC article. Review.
-
Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche.Cancer Res. 2018 Jun 1;78(11):2990-3001. doi: 10.1158/0008-5472.CAN-17-2319. Epub 2018 Mar 6. Cancer Res. 2018. PMID: 29510995 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
